Fig. 1

Impact of TNF neutralization by infliximab on the course of IL-6 (a) and lymphocytes (b) in severe COVID-19. Gray bar and dotted lines indicate Q1 and Q3 and median of 15 contemporary control patients, respectively. Solid lines indicate the individual course of seven patients treated with infliximab. Red: course of the non-survivor receiving infliximab